Statements (114)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired |
gptkb:Upjohn
|
| gptkbp:acquisition |
gptkb:Upjohn_division_of_Pfizer
gptkb:Upjohn gptkb:Merck_KGa_A's_biosimilars_business gptkb:Merck_KGa_A's_generics_business Boehringer Ingelheim's generic business expanded product portfolio Agila Specialties Upjohn in 2020 |
| gptkbp:acquisition_year |
gptkb:2019
gptkb:2020 |
| gptkbp:business_model |
generic and specialty drugs
|
| gptkbp:ceo |
gptkb:Heather_Bresch
|
| gptkbp:community_engagement |
various programs
|
| gptkbp:employees |
over 35,000
|
| gptkbp:financial_performance |
publicly traded
|
| gptkbp:focus |
generic drugs
affordable medicines access to medicines specialty drugs |
| gptkbp:founded |
gptkb:1961
|
| gptkbp:founder |
Milton P. H. H. Mylan
Milton P. H. H. H. Mylan |
| gptkbp:global_presence |
over 165 countries
|
| gptkbp:head_of_state |
gptkb:Rajiv_Malik
|
| gptkbp:headquarters |
gptkb:Canonsburg,_Pennsylvania
gptkb:Pennsylvania gptkb:United_States Canonsburg Viatris, Canonsburg, Pennsylvania |
| https://www.w3.org/2000/01/rdf-schema#label |
Mylan
|
| gptkbp:key_people |
gptkb:Heather_Bresch
|
| gptkbp:market |
global
generic pharmaceuticals global pharmaceutical market |
| gptkbp:marketing_strategy |
affordable medications
|
| gptkbp:merged_with |
gptkb:Pfizer
with Upjohn to form Viatris |
| gptkbp:operates_in |
global markets
|
| gptkbp:parent_company |
gptkb:Viatris
|
| gptkbp:partnership |
gptkb:GSK
gptkb:pharmaceuticals gptkb:Astra_Zeneca gptkb:Sanofi gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb gptkb:Baxter_International gptkb:Pfizer gptkb:Merck_&_Co. gptkb:Roche gptkb:Sandoz gptkb:Eli_Lilly_and_Company gptkb:Abb_Vie gptkb:Novartis Biosimilars with Biocon |
| gptkbp:partnerships |
various healthcare organizations
|
| gptkbp:products |
generic drugs
specialty pharmaceuticals generic and specialty pharmaceuticals |
| gptkbp:regulatory_compliance |
follows global standards
|
| gptkbp:research_and_development |
invests heavily
|
| gptkbp:research_areas |
gptkb:diabetes
gptkb:supply_chain_management gptkb:surgery research and development quality assurance palliative care clinical trials community outreach neurology oncology pediatrics rehabilitation market access psychiatry dermatology critical care hormonal therapies infectious diseases emergency medicine immunology pain management pharmacovigilance women's health health economics nursing ophthalmology patient support programs geriatrics transplantation urology gastroenterology regulatory affairs cardiovascular men's health respiratory addiction medicine medical affairs healthcare professional education |
| gptkbp:revenue |
$11.5 billion (2020)
11.4 billion USD (2020) $11.4 billion (2019) 11.4 billion USD (2019) |
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:stock_symbol |
MYL
|
| gptkbp:strategic_goals |
improve global health
|
| gptkbp:subsidiary |
gptkb:Mylan_N._V.
|
| gptkbp:sustainability_efforts |
focus on access
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
www.mylan.com
|
| gptkbp:bfsParent |
gptkb:pharmaceuticals
gptkb:Pfizer |
| gptkbp:bfsLayer |
4
|